[go: up one dir, main page]

NO20025651L - Adenosin A2A-reseptorantagonister - Google Patents

Adenosin A2A-reseptorantagonister

Info

Publication number
NO20025651L
NO20025651L NO20025651A NO20025651A NO20025651L NO 20025651 L NO20025651 L NO 20025651L NO 20025651 A NO20025651 A NO 20025651A NO 20025651 A NO20025651 A NO 20025651A NO 20025651 L NO20025651 L NO 20025651L
Authority
NO
Norway
Prior art keywords
optionally substituted
phenyl
parkinson
heteroaryl
disease
Prior art date
Application number
NO20025651A
Other languages
English (en)
Other versions
NO20025651D0 (no
NO325008B1 (no
Inventor
Bernard R Neustadt
Neil A Lindo
William J Greenlee
Deen Tulshian
Lisa S Silverman
Yan Xia
Craig D Boyle
Samuel Chackalamannil
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20025651D0 publication Critical patent/NO20025651D0/no
Publication of NO20025651L publication Critical patent/NO20025651L/no
Publication of NO325008B1 publication Critical patent/NO325008B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Det beskrives forbindelser med strukturformelen (I). eller et farmasøytisk aksepterbart salt derav, hvori R er om ønskelig substituert fenyl, sykloalkenyl eller heteroaryl, X er alkylen eller -C(0)CH-, Y er -N(R)CHCHN(R)-, - OCHCHN(R)-, -O-, -S-, -CHS-, -(CH)-NH-, eller eventuelt substituert, (Ia),m og n er 2-3, og Q er nitrogen eller eventuelt substituert karbon, og Z er eventuelt substituert fenyl, fenylalkyl eller heteroaryl, difenylmetyl, RC(0)-, R6-S02-, R6-OC(0)-, RN(R)-C(0)-, RN(R)-C(S)-, fenyl-CH(OH)- eller fenyl- C(=NOR) -, eller dersom Q er CH, a),. fenylamino eller pyridylamino, eller hvori Z og Y sammen er substituert piperidinyl eller substituert fenyl, og R, R, R, Rog Rer som definert i beskrivelsen, anvendelse av disse ved behandling av Parkinsons sykdom, alene eller i kombinasjon med andre midler for behandling av Parkinsons sykdom, og farmasøytiske preparater som inneholder dem; videre beskrives en fremgangsmåte for fremstilling av intermediater som er anvendbare for fremstilling av forbindelser med formel (I).
NO20025651A 2000-05-26 2002-11-25 Adenosin A2A-reseptorantagonister NO325008B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20714300P 2000-05-26 2000-05-26
PCT/US2001/016954 WO2001092264A1 (en) 2000-05-26 2001-05-24 Adenosine a2a receptor antagonists

Publications (3)

Publication Number Publication Date
NO20025651D0 NO20025651D0 (no) 2002-11-25
NO20025651L true NO20025651L (no) 2003-01-23
NO325008B1 NO325008B1 (no) 2008-01-14

Family

ID=22769372

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025651A NO325008B1 (no) 2000-05-26 2002-11-25 Adenosin A2A-reseptorantagonister

Country Status (31)

Country Link
US (4) US6630475B2 (no)
EP (1) EP1283839B1 (no)
JP (3) JP4574112B2 (no)
KR (1) KR100520907B1 (no)
CN (2) CN1247588C (no)
AR (1) AR028621A1 (no)
AT (1) ATE293627T1 (no)
AU (2) AU6808901A (no)
BR (1) BRPI0111015B8 (no)
CA (1) CA2410237C (no)
CZ (1) CZ303790B6 (no)
DE (1) DE60110219T2 (no)
DK (1) DK1283839T3 (no)
EC (1) ECSP024364A (no)
ES (1) ES2237576T3 (no)
HK (1) HK1049007B (no)
HU (1) HU230420B1 (no)
IL (3) IL152726A0 (no)
MX (1) MXPA02011625A (no)
MY (1) MY132006A (no)
NO (1) NO325008B1 (no)
NZ (1) NZ522326A (no)
PE (1) PE20020062A1 (no)
PL (1) PL218764B1 (no)
PT (1) PT1283839E (no)
RU (1) RU2315053C2 (no)
SI (1) SI1283839T1 (no)
SK (1) SK287748B6 (no)
TW (1) TWI288137B (no)
WO (1) WO2001092264A1 (no)
ZA (1) ZA200208898B (no)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6808901A (en) * 2000-05-26 2001-12-11 Schering Corp Adenosine a2a receptor antagonists
JP2005516891A (ja) * 2001-09-13 2005-06-09 シェーリング　コーポレイション アデノシンＡ２ａレセプタアンタゴニストと抗鬱薬または抗不安薬との組合せ
IL160878A0 (en) 2001-10-15 2004-08-31 Schering Corp Imidazo (4,3-e)-1,2,4-triazolo (1,5-c) pyrimidines as adenosine a2a receptor antagonists
FR2832405B1 (fr) * 2001-11-19 2004-12-10 Sanofi Synthelabo Tetrahydropyridyl-alkyl-heterocycles azotes, procede pour leur preparation et compositions pharmaceutiques les contenant
PE20030739A1 (es) 2001-11-30 2003-08-28 Schering Corp Antagonistas del receptor de adenosina a2a
MXPA04005209A (es) * 2001-11-30 2004-08-19 Schering Corp Antagonistas del receptor de adenosina a2a.
MXPA04005158A (es) 2001-11-30 2004-08-11 Schering Corp Antagonistas receptores de adenosina a2a biciclica de (1.2.4]- triazol.
CN101822676A (zh) 2002-01-28 2010-09-08 协和发酵麒麟株式会社 治疗运动疾病患者的方法
EP1549319A2 (en) 2002-05-30 2005-07-06 King Pharmaceuticals Research and Development Inc. Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
US20060106040A1 (en) * 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
EP2269596A3 (en) * 2002-12-19 2011-09-14 Schering Corporation Use of adenosine A2a receptor antagonists for the treatment of extrapyramidal syndrome and other movement disorders
US20070010522A1 (en) 2003-04-09 2007-01-11 Chi Vu Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists
PE20050141A1 (es) 2003-04-23 2005-04-01 Schering Corp DERIVADOS DE 2-ALQUINIL-Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIDINA COMO ANTAGONISTAS DEL RECEPTOR A2a ADENOSINA
US8202869B2 (en) * 2003-06-10 2012-06-19 Kyowa Hakko Kirin Co., Ltd. Method of treating an anxiety disorder
JP2006527212A (ja) * 2003-06-12 2006-11-30 ノボ　ノルディスク　アクティーゼルスカブ ホルモン感受性リパーゼの阻害剤として使用するための、置換ピペラジンカルバメート
JP4800216B2 (ja) * 2003-10-24 2011-10-26 エグゼリクシス， インコーポレイテッド ｐ７０Ｓ６キナーゼモジュレーターおよび使用方法
WO2005044819A1 (en) 2003-10-28 2005-05-19 Schering Corporation Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines
CA2547248A1 (en) * 2003-12-01 2005-06-16 Schering Corporation Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines
AU2004303425C1 (en) * 2003-12-19 2010-02-18 Schering Corporation Pharmaceutical compositions
TW200538118A (en) 2004-04-21 2005-12-01 Schering Corp Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
EP2258372B8 (en) 2005-06-07 2012-12-19 Kyowa Hakko Kirin Co., Ltd. A2A antagonists for use in the treatment of motor disorders
ATE538123T1 (de) * 2005-09-19 2012-01-15 Schering Corp 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors
PE20070521A1 (es) * 2005-09-23 2007-07-13 Schering Corp 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
JP5539717B2 (ja) * 2006-07-14 2014-07-02 塩野義製薬株式会社 オキシム化合物およびその使用
TW200840566A (en) * 2006-12-22 2008-10-16 Esteve Labor Dr Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments
US7723343B2 (en) * 2007-03-30 2010-05-25 King Pharmaceuticals Research And Development, Inc. Adenosine A2A receptor antagonists
US8669260B2 (en) * 2008-02-29 2014-03-11 Albert Einstein College Of Medicine Of Yeshiva University Ketoconazole-derivative antagonist of human pregnane X receptor and uses thereof
EP2262811B1 (en) 2008-03-04 2016-04-27 Merck Sharp & Dohme Corp. 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e]-1,2,4-triazolo [4,3-c]pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists
EP2274007B1 (en) 2008-03-10 2016-12-14 Cornell University Modulation of blood brain barrier permeability
TWI473614B (zh) 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
BRPI0916203A2 (pt) 2008-07-23 2018-05-15 Kyowa Hakko Kirin Co Ltd agente terapêutico e/ou preventivo para enxaqueca, método para tratar e/ou prevenir enxaqueca, e, uso de um composto
US20100093702A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US8273754B2 (en) 2008-12-30 2012-09-25 Arqule, Inc. Substituted 1H-pyrazolo[3,4-D]pyrimidine-6-amine compounds
MX2011007678A (es) 2009-01-20 2011-08-08 Schering Corp Metodos para aliviar o tratar señales y/o sintomas asociados con enfermedad de parkinson de moderada a severa.
WO2010084160A1 (en) 2009-01-21 2010-07-29 Oryzon Genomics S.A. Phenylcyclopropylamine derivatives and their medical use
AU2010222289B2 (en) 2009-03-13 2013-07-11 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
CA2756871A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted heterocyclic compounds
US8537177B2 (en) * 2009-06-15 2013-09-17 Marvell World Trade Ltd. System and methods for gamut bounded saturation adaptive color enhancement
EP2462144B1 (en) 2009-08-07 2017-09-20 Merck Sharp & Dohme Corp. PROCESS FOR PREPARING A 2-ALKYNYL SUBSTITUTED 5-AMINO-PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE
KR101736218B1 (ko) 2009-09-25 2017-05-16 오리존 지노믹스 에스.에이. 라이신 특이적 디메틸라아제-1 억제제 및 이의 용도
WO2011042217A1 (en) 2009-10-09 2011-04-14 Oryzon Genomics S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
WO2011106106A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
WO2011106105A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
JP5868948B2 (ja) 2010-04-19 2016-02-24 オリゾン・ジェノミックス・ソシエダッド・アノニマＯｒｙｚｏｎ Ｇｅｎｏｍｉｃｓ Ｓ．Ａ． リジン特異的脱メチル化酵素１阻害薬およびその使用
EP2598480B1 (en) 2010-07-29 2019-04-24 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
EP3375775A1 (en) 2010-07-29 2018-09-19 Oryzon Genomics, S.A. Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
CN103261202B (zh) * 2010-09-24 2016-01-20 阿迪维纳斯疗法有限公司 作为腺苷受体拮抗剂的稠合三环化合物
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP2712315B1 (en) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
WO2012129381A1 (en) * 2011-03-22 2012-09-27 Concert Pharmaceuticals Inc. Deuterated preladenant
WO2012127472A1 (en) * 2011-03-22 2012-09-27 Mapi Pharma Ltd. Process and intermediates for the preparation of preladenant and related compounds
WO2013024474A1 (en) * 2011-08-18 2013-02-21 Mapi Phrarma Ltd. Polymorphs of preladenant
IL264982B (en) 2011-10-20 2022-08-01 Oryzon Genomics Sa Hetero(aryl)cyclopropylamine compounds as lsd1 inhibitors
US9487512B2 (en) 2011-10-20 2016-11-08 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
WO2014071512A1 (en) * 2012-11-06 2014-05-15 Universite Laval Combination therapy and methods for the treatment of respiratory diseases
WO2014101120A1 (en) * 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
RU2727805C2 (ru) 2014-11-18 2020-07-24 Мерк Шарп И Доум Корп. Аминопиразиновые соединения со свойствами антагониста a2a
US10138212B2 (en) 2015-02-06 2018-11-27 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as A2A antagonist
WO2016200717A1 (en) 2015-06-11 2016-12-15 Merck Sharp & Dohme Corp. Aminopyrazine compounds with a2a antagonist properties
WO2017008205A1 (en) 2015-07-10 2017-01-19 Merck Sharp & Dohme Corp. Substituted aminoquinazoline compounds as a2a antagonist
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
WO2018178338A1 (en) * 2017-03-30 2018-10-04 Iteos Therapeutics 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
CN115873022A (zh) * 2017-03-30 2023-03-31 伊忒欧斯比利时股份公司 作为a2a抑制剂的2-氧代噻唑衍生物和用于治疗癌症的化合物
US11498923B2 (en) 2017-12-13 2022-11-15 Merck Sharp & Dohme Llc Substituted imidazo[1,2-c]quinazolines as A2A antagonists
SG11202006435XA (en) 2018-01-04 2020-08-28 Impetis Biosciences Ltd Tricyclic compounds, compositions and medicinal applications thereof
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
CN108276345A (zh) * 2018-03-22 2018-07-13 重庆奥舍生物化工有限公司 一种药物中间体嘧啶-5-甲醛的制备方法
EA202092036A1 (ru) 2018-04-08 2021-01-28 Бейджин, Лтд. Производные пиразолотриазолопиримидина в качестве антагониста рецептора a2a
MX2020012376A (es) 2018-05-18 2021-03-09 Incyte Corp Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
CN108864114B (zh) * 2018-06-04 2020-11-06 应世生物科技(南京)有限公司 选择性a2a受体拮抗剂
US11161850B2 (en) 2018-07-05 2021-11-02 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
CN110742893B (zh) * 2018-07-23 2024-04-05 百济神州(北京)生物科技有限公司 A2a受体拮抗剂治疗癌症的方法
WO2020112700A1 (en) 2018-11-30 2020-06-04 Merck Sharp & Dohme Corp. 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
SG11202106582YA (en) 2018-12-20 2021-07-29 Incyte Corp Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US12325708B2 (en) 2019-05-03 2025-06-10 Nektar Therapeutics Adenosine 2 receptor antagonists
DE102019116986A1 (de) 2019-06-24 2020-12-24 Helmholtz-Zentrum Dresden-Rossendorf E. V. Deuterierte 7-(3-(4-(2-([18F]Fluor)ethoxy)phenyl)propyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amin-Derivate
JP2022540583A (ja) * 2019-07-17 2022-09-16 テオン セラピューティクス，インク． アデノシンａ２ａ受容体アンタゴニスト及びその使用
CN112625050B (zh) 2019-07-30 2021-10-01 杭州阿诺生物医药科技有限公司 一种a2a和/或a2b受体抑制剂的制备方法
CN112500416B (zh) 2019-07-30 2021-12-17 厦门宝太生物科技股份有限公司 一种吡唑并三嗪类化合物中间体的制备方法
CN111072675A (zh) * 2019-12-12 2020-04-28 广东东阳光药业有限公司 含氮稠合三环衍生物及其用途
CN113773327B (zh) * 2021-09-13 2022-07-15 八叶草健康产业研究院(厦门)有限公司 一种吡唑并嘧啶并三唑环类化合物的制备方法
CN118812544A (zh) * 2024-06-19 2024-10-22 厦门大学 一种腺苷a2ar靶向小分子化合物、核素标记探针及其制备方法、应用和药物组合物
CN118812539B (zh) * 2024-06-19 2025-11-28 苏州大学 一种5-氨基三唑并嘧啶衍生物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0217748B1 (en) 1985-09-30 1991-02-06 Ciba-Geigy Ag 2-Substituted-e-fused-[1,2,4,]triazolo-[1,5-c]pyrimidines pharmaceutical compositions and uses thereof
SU1739850A3 (ru) * 1987-08-31 1992-06-07 Такеда Кемикал Индастриз, Лтд (Фирма) Способ получени конденсированных производных пиразоло[3,4- @ ]пиримидина
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
AU7237294A (en) 1993-07-27 1995-02-28 Kyowa Hakko Kogyo Co. Ltd. Remedy for parkinson's disease
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) * 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
AU6808901A (en) * 2000-05-26 2001-12-11 Schering Corp Adenosine a2a receptor antagonists
MXPA04005209A (es) * 2001-11-30 2004-08-19 Schering Corp Antagonistas del receptor de adenosina a2a.
EP2269596A3 (en) * 2002-12-19 2011-09-14 Schering Corporation Use of adenosine A2a receptor antagonists for the treatment of extrapyramidal syndrome and other movement disorders
WO2005044819A1 (en) * 2003-10-28 2005-05-19 Schering Corporation Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines
CA2547248A1 (en) * 2003-12-01 2005-06-16 Schering Corporation Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines
TW200538118A (en) * 2004-04-21 2005-12-01 Schering Corp Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
ATE538123T1 (de) * 2005-09-19 2012-01-15 Schering Corp 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors

Also Published As

Publication number Publication date
SK16712002A3 (sk) 2003-08-05
NZ522326A (en) 2006-03-31
BRPI0111015B1 (pt) 2017-11-07
JP2007145875A (ja) 2007-06-14
US7067655B2 (en) 2006-06-27
CZ303790B6 (cs) 2013-05-09
DE60110219D1 (de) 2005-05-25
CZ20023886A3 (cs) 2003-02-12
EP1283839B1 (en) 2005-04-20
ES2237576T3 (es) 2005-08-01
IL152726A0 (en) 2003-06-24
ECSP024364A (es) 2003-03-31
ZA200208898B (en) 2004-03-01
US20050026932A1 (en) 2005-02-03
NO20025651D0 (no) 2002-11-25
MXPA02011625A (es) 2003-03-27
US20040023997A1 (en) 2004-02-05
CN1247588C (zh) 2006-03-29
CN1800186A (zh) 2006-07-12
JP2003535094A (ja) 2003-11-25
BRPI0111015B8 (pt) 2021-05-25
JP4574112B2 (ja) 2010-11-04
JP4938348B2 (ja) 2012-05-23
ATE293627T1 (de) 2005-05-15
KR100520907B1 (ko) 2005-10-11
KR20030003746A (ko) 2003-01-10
EP1283839A1 (en) 2003-02-19
US20020099061A1 (en) 2002-07-25
RU2315053C2 (ru) 2008-01-20
PL360472A1 (en) 2004-09-06
IL220174A0 (en) 2012-07-31
US6897216B2 (en) 2005-05-24
HUP0600239A3 (en) 2008-06-30
HK1049007A1 (en) 2003-04-25
CN100384847C (zh) 2008-04-30
PL218764B1 (pl) 2015-01-30
TWI288137B (en) 2007-10-11
AU2001268089B2 (en) 2005-04-28
HU230420B1 (hu) 2016-05-30
AR028621A1 (es) 2003-05-14
MY132006A (en) 2007-09-28
USRE44205E1 (en) 2013-05-07
HK1049007B (en) 2005-09-16
SI1283839T1 (no) 2005-08-31
CN1451007A (zh) 2003-10-22
AU2001268089C1 (en) 2006-04-13
NO325008B1 (no) 2008-01-14
IL220174A (en) 2015-07-30
JP2006219497A (ja) 2006-08-24
WO2001092264A1 (en) 2001-12-06
CA2410237A1 (en) 2001-12-06
SK287748B6 (sk) 2011-08-04
IL152726A (en) 2012-07-31
AU6808901A (en) 2001-12-11
BR0111015A (pt) 2005-01-11
DE60110219T2 (de) 2006-03-09
US6630475B2 (en) 2003-10-07
DK1283839T3 (da) 2005-07-25
HUP0600239A2 (en) 2006-07-28
PT1283839E (pt) 2005-08-31
CA2410237C (en) 2008-01-08
PE20020062A1 (es) 2002-02-02

Similar Documents

Publication Publication Date Title
NO20025651L (no) Adenosin A2A-reseptorantagonister
MY124864A (en) Adenosine a2a receptor antagonists
NO20060972L (no) Pyridylderivater og deres anvendelse som terapeutiske midler
AR031069A1 (es) Cristal de un compuesto benzimidazol, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima
HUP0400365A2 (hu) 3-Fluor-pirrolidinek, mint cukorbetegség elleni szerek és a vegyületeket tartalmazó gyógyszerkészítmények
NO20060974L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
NO982950L (no) Fenyltiazolderivater med inti-herpesvirus-egenskaper
NO20051695L (no) Nye spirokondenserte kinazolinoner og deres anvendelse som fosfodiestereaseinbibitorer
MX9604020A (es) Arilalquildiazinonas.
HK1046688A1 (zh) 喹唑啉化合物和含有喹唑啉化合物的藥物組合物
NO20064166L (no) Utvalgte CGRP-antagonister, deres fremstilling og deres anvendelse som medikanmenter
HUP0004076A2 (hu) C-4"-Szubsztituált-makrolid-származékok
NO20075059L (no) Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase
AU2003302416A1 (en) Therapeutic agent for respiratory disease containing 4-hydroxypiperidine derivative as active ingredient
CA2238875A1 (en) Tri-aryl ethane derivatives as pde iv inhibitors
NO20022124L (no) Imidazopyridinderivater som fosfodiesterase VII-inhibitorer
NO20044545L (no) Piperidin-eller 8-aza-bicyklo[3.2.1.]okt-3-yl derivater som er nyttige som modulatorer for kemokireseptoraktivitet (spesielt CCR5)
NO20060147L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
BR0213327A (pt) Derivados de 4-fenil-4-[1h-imidazol-2-il]-piperidina substituìdos e sua aplicação como agonistas de delta opióides não-peptìdicos seletivos
NO20052698L (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gasatrintestinale lidelser.
NO20050573L (no) 4-'7-halo-2-quino (XA) linyloksy ! fenoksypropionsyrederivater som antineoplastiske midler
CA2465871A1 (en) Heteroaryl derivatives as superior ligands for nociceptin receptor orl-1
NO20022123L (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
DK1412332T3 (da) Quinolinderivater og anvendelse deraf som antitumormidler
BRPI0313976B8 (pt) compostos de 7-fenilpirazolopiridina e uso dos mesmos na preparação de agente terapêutico ou profilático para doenças associadas com o crf ou seus receptores

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY, US

MK1K Patent expired